Edgewise: DMD data in first half of 2024 could lead to further testing (NASDAQ: EWTX)

fatido/iStock via Getty Images

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is continuing the Phase 2 LYNX trial using its drug EDG-5506 in children ages 4 to 9 with Duchenne muscular dystrophy (DMD). She also decided to add a